The European Society of Cardiology (ESC) recently updated its guidelines. Consequently, based on the EMPEROR-Preserved and DELIVER trials, the use of SGLT-2 inhibitors is now recommended for all stages of heart failure. Thus, in addition to HFrEF, HFmrEF and HFpEF are now class IA indications for dapagliflozin or empagliflozin. In clinical trials, the use of SGLT-2 inhibitors has significantly reduced hospitalizations due to heart failure in particular.
This content is machine-translated. Please contact us if you need professional translation services.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Suspicion of coronary heart disease
Stress echocardiography, MR heart or computed tomography heart?
- Cardiorenal syndrome
Cross-talk between heart and kidney
- Chronic urticaria
“Treat-to-target” approach is underpinned by new findings
- Dual GIP/GLP-1 RA in type 2 diabetes
Tirzepatide proves multiple benefits
- Pain syndrome
From pathophysiology to therapy – a reminder
- Sunscreen
Increasing risk of skin cancer due to dangerous UV radiation
- Coronary heart disease and type 2 diabetes
Relationship between baseline FFA values and all-cause mortality.
- Esophagus